Background
==========

Epidemiology
------------

Hepatitis C virus (HCV) is an asymptomatic disease and, as such, is treated mainly at an advanced stage.[@b1-ceor-8-377] However, the clinical evolution of HCV infection in the medium and long terms may lead to liver compensated and decompensated cirrhosis, hepatocellular carcinoma (HCC), liver transplant, and eventually to death. Among the patients who suffer from HCV infection, in fact, \>90% become chronic carriers, among them 65%--95% develop chronic liver disease, and in 10%--30% of the cases, an evolution into cirrhosis is observed within 25--30 years.[@b2-ceor-8-377] Cirrhotic subjects have a yearly probability between 1% and 3% to develop HCC.[@b3-ceor-8-377]

HCV affects an estimated number between 130 million and 210 million people worldwide.[@b4-ceor-8-377] According to the findings of a study conducted in 2014 by the European Centre for Disease Prevention and Control, Italy has the highest number of HCV-positive patients in Europe and the highest rate of death from cirrhosis and HCC.[@b5-ceor-8-377] The significant epidemiological impact of the disease will lead the Italian National Health Service (NHS) in the next 5--10 years to offer an increasing number of HCV-related health services to a growing number of patients.[@b2-ceor-8-377]

Management of chronic HCV
-------------------------

In the last 2 years, several new drugs have been authorized in the European market, with a therapy duration of few weeks, with less side effects than the first-generation protease inhibitors and with a high percentage of sustained virological response, defined as "undetectable HCV RNA 12 weeks or 24 weeks after treatment completion".[@b6-ceor-8-377] In 2015, the European Association for the Study of Liver published therapeutic recommendations for the treatment of HCV infection, divided by HCV genotype.[@b6-ceor-8-377]

In addition to the aforementioned treatment recommendations, in Italy further management tools were introduced in the regulation of drug treatment for HCV: a centralized log monitoring, the identification of HCV antiviral treatment prescribing centers by the Regional Health Services, and the identification of seven criteria by the Italian Medicines Agency (AIFA) to prioritize patients to be treated, and select the most appropriate antiviral therapy to be administered.[@b7-ceor-8-377] In the Italian context, all the health costs for the patients admitted to the pharmacological therapy for HCV are fully covered by the Regional Health Service.

At a regional level (the public payor), the management tools introduced for the disease are the identification of reference treatment centers (373 in Italy), setting of annual budgets (different in each region considering the estimated number of target patients), and the collection of bottom-up clinical information of each treated patient.

The cost of pathology
---------------------

HCV is not only a considerable social burden but also an important chapter of NHS spending. In the next few years, the Italian NHS will face a growing trend of patients requiring HCV antiviral treatments (around 30,000 patients started antiviral treatment in 2015).[@b8-ceor-8-377] In terms of economic weight, new antiviral drugs for the treatment of HCV have increased their impact on the total NHS financing up to 0.45% in 2015 (considering the €0.5 billion allocated in 2015 for purchasing HCV antiviral treatments over the Italian NHS budget of €109.7 billion).

The literature highlights how treatment costs increase with the degree of severity of patients' condition:[@b9-ceor-8-377],[@b10-ceor-8-377] per patient direct and indirect costs are mainly absorbed by cirrhotic patients and those affected by advanced forms of liver disease.[@b10-ceor-8-377] In the same study, the annual direct and indirect costs of the disease in Italy are estimated to be €418 million and €643 million, respectively, reaching a total of €1.061 billion. The total costs for chronic HCV patients are €256 million, cirrhotic patients €560 million, patients affected with HCC €50 million, and patients admitted to liver transplant €48 million, and costs due to patients' death equal to €146 million.

Vietri et al (2013)[@b11-ceor-8-377] assessed the indirect and direct costs of the pathology in 2010, comparing self-reported outcomes (absenteeism and presenteeism) and use of resources in a sample of 286 HCV-infected patients from five European countries (Italy, France, Germany, the United Kingdom, and Spain) with a matched control sample of patients with similar demographic and health characteristics. The results of the analysis for the Italian environment show higher working and activity impairments and health care use in the HCV-infected group compared with the control group. The indirect mean annual costs per patient were €7,532.54 in HCV-infected patients vs €4,576.43 in the control group (*P*=0.002), and the direct mean annual costs per patient (physician visits, emergency room visits, and hospitalizations) were €1,147.06 and €652.07 (*P*\<0.001) in HCV-infected patients and control group, respectively.

In 2015, the research group of the University of Tor Vergata, Rome, published the first Italian pharmacoeconomic model that describes the epidemiological and economic burden (both direct and indirect medical costs) that HCV is expected to have up to 2020, 2030, and 2040 on the Italian NHS assuming the use of the first-generation protease inhibitors, boceprevir and telaprevir, of peginterferon-alfa + ribavirin and the second-generation treatments.[@b12-ceor-8-377] They also estimated that there will be a reduction of \>156,000 HCV-related events and a reduction in health care costs between €13,000 and €18,000 per treated patient in a 10- to 30-year time horizon.

Objectives
----------

Considering the lack of a structured study at a national level to assess the impact of the second-generation pharmacological treatments for HCV infection in Italy, the aim of the analysis presented was to estimate the total cost of the treatment and the related parameters (eg, time horizon for treatment period and NHS treatment capacity) referring to the most recent treatment recommendations[@b6-ceor-8-377] by developing a static deterministic model and using both top-down and bottom-up approaches to identify the number of HCV-infected patients. The point of view considered is that of the Italian NHS.

Methodology
===========

Epidemiology
------------

The number of HCV-infected patients in Italy was estimated using two different approaches. First, a top-down approach was used considering the published data related to the Italian context in terms of regional prevalence,[@b13-ceor-8-377] genotype distribution,[@b14-ceor-8-377] and fibrosis stage[@b15-ceor-8-377] ([Table 1](#t1-ceor-8-377){ref-type="table"}).

The combination of the data referred to prevalence, genotypes, and liver fibrosis stages distribution among the Italian population (considering the Italian Resident Population on January 1, 2015)[@b16-ceor-8-377] ([Table 1](#t1-ceor-8-377){ref-type="table"}) leads to the regional estimation presented in [Table 2](#t2-ceor-8-377){ref-type="table"}. The total number of HCV-infected subjects in Italy using a top-down approach is estimated to be 2,688,444.

Second, a bottom-up approach was also used to estimate the emerged cases of HCV infection in Italy, identified through data available in literature that were collected thriough the records of the Italian NHS. The number of patients with an exemption from copayment due to HCV condition (which in the Italian NHS is certified by local health authorities) is 308,624.[@b17-ceor-8-377] Further patients should be included: 20,640 HIV coinfected patients (identified through the Italian Cohort Naive Antiretrovirals)[@b17-ceor-8-377] and 3,860 estimated patients in prison detention (number of persons in prison detention on December 31, 2015, and HCV prevalence among the prisoners).[@b18-ceor-8-377],[@b19-ceor-8-377] Moreover, the number of HCV-infected patients, aware of their condition and who benefit from low-income exemption from copayment (total exemption from all copayments in the NHS than for only copayment for HCV-related treatments, which is more valuable for patients) should be estimated. In Italy, according to the Ministry of Health data, 6,930,000 patients are exempt from copayment because of low income (46.2% of the total exemptions from copayment for any reason in Italy).[@b20-ceor-8-377] Among them, using the national age-adjusted prevalence rate of 4.4%,[@b13-ceor-8-377] further 304,920 HCV-infected patients are estimated. Therefore, the total number of patients with a diagnosis of HCV infection in Italy is estimated to be within a range from 329,264 to 613,124.

Comparing the results of bottom-up and top-down analyses, we can state that the number of HCV-infected patients in Italy is between 0.3 million and 2.7 million. Considering the number of reference treatment centers activated in Italy at a regional level,[@b21-ceor-8-377] the average number of patients to be treated per center is estimated to be 7.208 for the 2.7 million prevalence scenario, 1.711 for the 0.6 million prevalence scenario, and 883 for the 0.3 million prevalence scenario.

Economic analysis
-----------------

Starting from prevalence data and the European antiviral treatment guidelines (considering the information available on pharmaceutical companies' cost-volume agreements), we estimated the total direct medical costs that Italian NHS should tackle in order to eliminate the virus in terms of direct medical costs related to antiviral treatment and monitoring activities (treating the entire infected population regardless of the fibrosis stage), developing a static deterministic model to assess the time period in which it would be possible to treat these patients, until reaching a prevalence below 100 HCV infections.

At time 0, patients are distributed among health states, characterized by different stages of evolution of the pathology (ie, fibrosis stages from 0 to 4, decompensated cirrhosis, HCC, and patients eligible for liver transplant). The patient distribution at time 0 is presented in [Table 3](#t3-ceor-8-377){ref-type="table"}. Mühlberger et al (2009)[@b22-ceor-8-377] reported that in Italy, every year, 1,050 patients enter the model in fibrosis stage 0 (F0), considering a mean incidence of 1.75 cases per 100,000 inhabitants. Each year, patients may change their health state (F0, F1, F2, F3, F4, decompensated cirrhosis, HCC, transplant year 1, transplant year 2+, and death) using the following rates of transition: from F0 to F1, 0.077; from F1 to F2, 0.092; from F2 to F3, 0.145; from F3 to F4, 0.116; from F4 to decompensated cirrhosis, 0.039; from F4 to HCC, 0.014; from decompensated cirrhosis to HCC, 0.014; from decompensated cirrhosis to liver transplant, 0.030; from HCC to liver transplant, 0.030; from decompensated cirrhosis to death, 0.130; from HCC to death, 0.430; from liver transplant (year 1) to death, 0.210; from liver transplant (year 2 and following years), 0.057.[@b23-ceor-8-377]--[@b25-ceor-8-377]

The distribution of patients in different health states in the baseline scenario (no patients treated) is compared with four different scenarios in which a fixed number of patients is treated with antiviral therapies in each yearly cycle: 25,000; 50,000; 75,000; and 100,000. Considering the number of reference treatment centers that were already authorized in Italy and the maximum number of weeks per treatment (24 weeks), we estimated an average number of patients to be managed by each center at the same time to be between 34 and 134 patients.

In the model, patients are treated starting from those associated with worst health states (eligible for a liver transplant the same year, HCC, decompensated cirrhosis, F4, F3, F2, F1, and F0). Based on the effectiveness of each antiviral treatment (as reported in [Table 4](#t4-ceor-8-377){ref-type="table"}), patients may reach a sustained virological response and exit the model or remain in the same health state and be retreated the following year.

The direct medical costs for treated patients include those of the antiviral treatment and of patient monitoring (ie, specialist visits, HCV-RNA test, alanine aminotransferase test, prothrombin time/international normalize ratio test, bilirubin test, and leukocyte count). Information concerning patient monitoring activities reflect the real clinical practice of two hospitals in Lombardy and Veneto regions, which are collected by interviewing key opinion leaders, and lead to a mean monitoring cost of €702 per treatment.

The cost of antiviral treatment was calculated considering the recommendations of the European Association for the Study of the Liver (2015),[@b6-ceor-8-377] divided by genotype and fibrosis stage, starting from the information available from the Italian Ministry of Health Official Gazette and official documentation. The costs related to each treatment recommended by the European Association for the Study of the Liver were then considered to select the less expensive antiviral therapy for each genotype and fibrosis stage (ie, genotype 1-infected patients with F0, F1, F2, F3, and F4 stages; genotype 2-infected patients with F0, F1, F2, F3, and F4 stages; etc). Two hypotheses were then considered: the possibility to use peginterferon within treatments and the sole use of interferon-free therapies.

The effectiveness parameters considered in the model, in terms of sustained virological response at 12 weeks, are those available in literature associated with the therapies considered per each genotype. The therapies within the two scenarios and the effectiveness parameters considered are reported in [Table 4](#t4-ceor-8-377){ref-type="table"}.

Effectiveness data were not available for all the direct-acting antiviral, genotype, and fibrosis conditions, therefore, overall effectiveness data for the unclustered patient population were considered in those cases. During the Social Affairs Commission of the Italian Parliament audition on November 16, 2015, the managing director of AIFA stated that price-volume agreement for Sofosbuvir considered a price of treatment of €750 million for 50,000 patients (€15,000 per treatment), with lower steps, down to €4,000 per treatment.[@b26-ceor-8-377] Considering the hypothetical cost batches, from €37,000 to €4,000, the mean cost per treatment of Sofosbuvir was estimated to be €16,353 (value-added tax inclusive). The cost of Sofosbuvir + Ledipasvir was considered to be 111.11% of the cost of Sofosbuvir as in the Italian Official Gazette documents,[@b27-ceor-8-377],[@b28-ceor-8-377] equal to €19,987 (value-added tax inclusive).

Due to lack of data concerning the price-volume agreement for Ombitasvir/Paritaprevir/Ritonavir and Ombitasvir/Paritaprevir/Ritonavir + Dasabuvir, and assuming it to be similar to the one described earlier, we considered the same price of Sofosbuvir and Sofosbuvir + Ledipasvir, respectively. The costs per treatment considered in the analysis, value-added tax inclusive, are presented in [Table 5](#t5-ceor-8-377){ref-type="table"}.

Results
=======

Economic analysis
-----------------

Considering the number of diagnosed HCV-infected patients emerged from the hypotheses presented in "Economic analysis" section (bottom-up assessment of 0.3 million patients, bottom-up estimation of 0.6 million patients, and top-down estimation of 2.7 million patients), it is possible to forecast the number of years required to treat the whole Italian HCV-infected population, starting from 2016. HCV treatments last for 8--12 weeks, up to 24 weeks, requiring a constant monitoring of patients during the whole curative process. In 2015, 30,000 HCV-infected patients were treated with antiviral treatments. Authorized referred centers have a higher capacity in terms of patients being treated yearly; therefore, different scenarios were considered in terms of number of annual treated patients: 25,000; 50,000; 75,000; and 100,000.

In [Table 6](#t6-ceor-8-377){ref-type="table"}, we report the estimated direct medical costs for antiviral treatment of the whole Italian HCV-infected population in the three scenarios presented and the year in which HCV prevalence would fall below 100 infected patients. The estimation has a 35-year time horizon, up to 2050.

The results of the strategy that consider the use of therapies with peginterferon-alfa lead to higher costs compared with the sole use of interferon-free antiviral therapies. This is due to the mean higher effectiveness of these treatments, leading to a lower number of retreatments. The 2.7 million HCV-infected patients scenario considering a number of yearly treated patients below 100,000 lead to a lack of treatment for all HCV-infected patients. In these scenarios, up to 2050, more than 0.16 million patients and up to 1.29 million patients would not have been treated with antiviral therapies.

Finally, in order to estimate the benefits deriving from the management of HCV infection, the number of deaths and the number of patients with HCCs and liver transplants due to HCV infection avoided due to treatments were estimated considering the most plausible hypothesis of prevalence and the number of treatments per year: 0.3 million and 0.6 million HCV-infected patients (derived from the bottom-up analysis) and 50,000 interferon-free treatments per year. The productivity condition (eg, human and structural resources) of the HCV antiviral treatments by authorized prescribing centers, in fact, could be enough to treat \~50,000 patients per year (with an estimated mean number of 67 patients to be managed per center at the same time). In order to deal with more patients, it would be necessary to activate further centers at a regional level.

Specifically, according to the aforementioned transition probabilities in the two scenarios (0.3 million and 0.6 million HCV-infected patients), the mean number of deaths avoided (compared with the do-nothing scenario) per year would be 3,518 and 7,657; the mean number of liver transplants avoided per year would be 606 and 1,220; and the mean number of HCCs avoided per year would be 1,013 and 2,411, respectively. Multiplying the annual average cost per patient affected by HCV-induced diseases (calculated by Marcellusi et al, 2015,[@b10-ceor-8-377] and converted to 2015 cost level using the annual average consumer prices inflation rate as calculated by the International Monetary Fund)[@b29-ceor-8-377] by the number of years spent by the estimated population with HCC, by the total number of avoided transplants and deaths, we estimated the direct and indirect costs saved due to antiviral treatments in the 0.3 million HCV-infected patients scenario to be equal to €4.21 billion in 8 years (direct costs of €0.14 billion and indirect costs of €4.07 billion), and in the 0.6 million HCV-infected patients scenario equal to €25.20 billion in 15 years (direct costs of €0.51 billion and indirect costs of €24.69 billion).

Discussion
==========

The estimation of the number of HCV-infected patients in Italy shows a high spread between the top-down and bottom-up approaches, with a difference of around 2.4 million patients, and it is a relevant health problem in the Italian population. Considering the lack of publications of prevalence studies conducted among a significant sample of patients and/or accurate sampling distributions, the authors consider the estimation through the bottom-up approach to be more reliable to identify the costs to be incurred by the Italian NHS.

Moreover, we consider the topic of eradication and disease control as highly challenging in the absence of an accurate monitoring program to diagnose HCV infection in patients unaware of the infection. Italy has a rate of incidence between 1 and 2.5 per 100,000 and a lack of increase of prevalent cases is probably already reached.

The cost of treatment could be difficult to reconcile with an annual budget for pharmaceutical treatment for the country in case of elimination/controlling of HCV infection considering the prevalence data presented earlier, with a yearly cost of treatment of \~€1 billion (€0.87 billion and €0.92 billion) in the scenarios of bottom-up analysis (almost 5.5% of the total public financing for pharmaceutical treatments of the Italian NHS). HCV infection elimination requires a programmatic approach that probably fits better with a multiyear investment plan (treating all patients in a short-term horizon and paying the treatment costs in a medium-/long-term horizon).

Further research studies in this field should concentrate on the assessment of the prevalence and incidence of the pathology and on the effectiveness of antiviral treatments in different HCV-infected patient subgroups (considering virus genotypes and degree of severity of the pathology).

The results of the analysis might be overestimated due to the use of a fixed incidence rate, which might decrease with the reduction of infected patients. Moreover, the model does not consider deaths due to other causes than HCV; therefore, long-term results might be overestimated.

The treatment of the highest number of patients per year would be important to avoid the progression of the pathology, with a relevant impact on the quality of life of patients and on avoided direct and indirect medical costs for the Italian NHS. The opportunity to defer antiviral drug payment over a longer time period should be negotiated by the Italian Government with the pharmaceutical companies, to meet the objective of eliminating HCV with a sustainable multiyear payment schedule. The opportunity to control/eliminate the infection is in fact valuable, and the benefits for patients and for the Italian NHS would be maximized while treating the highest number of patients in a short-term horizon (considering the productive capacity of health care providers), deferring payments in the long-term. Health care sector in general and the pharmaceutical sector in particular will face further situations of this kind, for example, immunology discoveries, and then all the NHS stakeholders (industry, government and insurance, and also patients) will have to identify suitable financial instruments to face the new expenditure required.

The eradication of the disease in the 2.7 million infected people scenario would require a long time horizon, not compatible with the treatment of all patients, and also the capacity of treatment of the referring hospital centers could be questioned.

Conclusion
==========

Italy has the highest prevalence of HCV-infected patients in Europe and the highest rate of deaths from cirrhosis and HCC, and the country needs a comprehensive approach to deal with this specific condition. The treatment of all HCV-infected patients in Italy (between 0.3 million and 2.7 million) is a challenging target for the financial implications of patient care, due to the number of specialist doctors needed and due to all other variables that affect the treatment of the disease.

In an environment with scarce resources, investments in health should be focused on those technologies that offer therapeutic efficacy rates high enough to allow the health services to amortize expenditures due to the savings induced by the treatments. In Italy, considering the two scenarios presented with 0.3 million and 0.6 million HCV-infected patients, HCV infection could be eliminated/controlled in a 10- to 15-year time horizon. In this framework, and in particular for chronic and potentially chronic diseases, a multidimensional approach such as Health Technology Assessment is strategic to support the evidence-based decision making. New highly expensive health technologies, both drugs and medical devices, will be available in different health care areas, determining the so-called competition between actions.

Finally, we observe that the relevant difference between patients conceivable through prevalence rates toward patients already aware of their HCV condition shows that the Italian NHS could face serious difficulties due to possible emergence of unaware HCV-infected patients due to antiviral treatment costs, population treatment time, and hospital production capacity.
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###### 

HCV prevalence, genotype distribution, and fibrosis stage distribution among the Italian HCV-infected population

  Identification category              Partition   \% value   Reference
  ------------------------------------ ----------- ---------- -------------------
  Prevalence (age-adjusted analysis)   North       1.6        [@b13-ceor-8-377]
  Central                              6.1                    
  Southern                             7.3                    
  Genotype                             1           52.4       [@b14-ceor-8-377]
  2                                    26.6                   
  3                                    9.8                    
  4                                    10.5                   
  5                                    0.7                    
  Fibrosis stage                       F0--F1      42         [@b15-ceor-8-377]
  F2                                   15                     
  F3                                   12                     
  F4 and cirrhosis                     31                     

**Abbreviation:** HCV, hepatitis C virus.

###### 

Regional estimation of the number of hepatitis C virus-infected patients divided by genotype and fibrosis stage using a top-down approach

  Top-down approach                                                                                                                                                  
  ----------------------------------------------------------------- --------- --------- --------- --------- --------- --------- --------- --------- -------- ------- -----------
  Piemonte[a](#tfn3-ceor-8-377){ref-type="table-fn"}                21,144    15,951    10,734    8,097     3,955     2,983     4,237     3,196     283      213     70,791
  Valle d'Aosta[a](#tfn3-ceor-8-377){ref-type="table-fn"}           613       463       311       235       115       86        123       93        8        6       2,053
  Lombardia[a](#tfn3-ceor-8-377){ref-type="table-fn"}               47,801    36,061    24,266    18,305    8,940     6,744     9,578     7,226     638      482     160,042
  Trentino-Alto Adige[a](#tfn3-ceor-8-377){ref-type="table-fn"}     5,046     3,807     2,562     1,932     944       712       1,011     763       67       51      16,895
  Veneto[a](#tfn3-ceor-8-377){ref-type="table-fn"}                  23,548    17,765    11,954    9,018     4,404     3,322     4,718     3,560     315      237     78,842
  Friuli-Venezia Giulia[a](#tfn3-ceor-8-377){ref-type="table-fn"}   5,864     4,424     2,977     2,246     1,097     827       1,175     887       78       59      19,634
  Liguria[a](#tfn3-ceor-8-377){ref-type="table-fn"}                 7,566     5,708     3,841     2,897     1,415     1,068     1,516     1,144     101      76      25,332
  Emilia-Romagna[a](#tfn3-ceor-8-377){ref-type="table-fn"}          21,268    16,045    10,796    8,145     3,977     3,001     4,262     3,215     284      214     71,208
  Toscana[b](#tfn4-ceor-8-377){ref-type="table-fn"}                 68,372    51,578    34,708    26,183    12,787    9,646     13,701    10,335    913      689     228,912
  Umbria[b](#tfn4-ceor-8-377){ref-type="table-fn"}                  16,302    12,298    8,275     6,243     3,049     2,300     3,267     2,464     218      164     54,580
  Marche[b](#tfn4-ceor-8-377){ref-type="table-fn"}                  28,255    21,315    14,343    10,820    5,284     3,987     5,662     4,271     377      285     94,599
  Lazio[b](#tfn4-ceor-8-377){ref-type="table-fn"}                   107,357   80,988    54,498    41,112    20,078    15,147    21,512    16,229    1,434    1,082   359,438
  Abruzzo[c](#tfn5-ceor-8-377){ref-type="table-fn"}                 29,033    21,902    14,739    11,118    5,430     4,096     5,818     4,389     388      292     97,205
  Molise[c](#tfn5-ceor-8-377){ref-type="table-fn"}                  6,832     5,154     3,468     2,617     1,278     964       1,369     1,033     91       69      22,874
  Campania[c](#tfn5-ceor-8-377){ref-type="table-fn"}                127,803   96,412    64,877    48,942    23,902    18,031    25,610    19,319    1,707    1,288   427,892
  Puglia[c](#tfn5-ceor-8-377){ref-type="table-fn"}                  89,180    67,275    45,271    34,151    16,679    12,582    17,870    13,481    1,191    899     298,578
  Basilicata[c](#tfn5-ceor-8-377){ref-type="table-fn"}              12,573    9,484     6,382     4,815     2,351     1,774     2,519     1,901     168      127     42,093
  Calabria[c](#tfn5-ceor-8-377){ref-type="table-fn"}                43,098    32,512    21,878    16,504    8,060     6,081     8,636     6,515     576      434     144,294
  Sicilia[c](#tfn5-ceor-8-377){ref-type="table-fn"}                 111,026   83,756    56,361    42,517    20,765    15,664    22,248    16,783    1,483    1,119   371,722
  Sardegna[b](#tfn4-ceor-8-377){ref-type="table-fn"}                30,304    22,861    15,383    11,605    5,668     4,275     6,072     4,581     405      305     101,460
  Italy                                                             802,987   605,758   407,623   307,503   150,177   113,290   160,904   121,383   10,727   8,092   2,688,444

**Notes:** Prevalence data:

North;

Central;

South. G1--G5 are genotype distributions. F0--F4 are fibrosis stages.

###### 

HCV-infected patient distribution in year 0

  Health state              Number of patients   Source              
  ------------------------- -------------------- --------- --------- ----------------------------------------------------------------------------------------------------------------------------------------------------
  F0                        69,145               128,756   564,573   Calculated considering data from reference 15
  F1                        69,145               128,756   564,573   
  F2                        49,390               91,969    403,267   
  F3                        39,512               73,575    322,613   
  F4                        66,644               132,641   615,153   
  Decompensated cirrhosis   22,215               44,214    205,051   Calculated considering a 3:1 ratio between compensated cirrhosis and decompensated cirrhosis[@b30-ceor-8-377]
  HCC                       12,850                                   Calculated considering the number of HCCs due to HCV, 60%,[@b31-ceor-8-377] from the 35,447 patients with HCC in Italy in 2015[@b32-ceor-8-377]
  Liver transplant          364                                      Calculated considering the 34.5% liver transplants due to HCV[@b33-ceor-8-377] among the 1,056 liver transplants in Italy in 2014[@b34-ceor-8-377]

**Note:** F0--F4 are fibrosis stages.

**Abbreviations:** HCC, hepatocellular carcinoma; HCV, hepatitis C virus.

###### 

HCV therapies considered in the model and related effectiveness parameters

  Scenario                          Genotype                             Antiviral treatment for noncirrhotic patients                                                    Antiviral treatment for cirrhotic patients                                                                                                                                                                                                                                                                                               
  --------------------------------- ------------------------------------ ------------------------------------------------------------------------------------------------ ------------------------------------------------------------------------------------------------ ------------------------------------ ------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------ ----
  All treatments available          Genotype 1                           Peg-IFN-α + RBV + SOF for 12 weeks                                                               89.38%[a](#tfn8-ceor-8-377){ref-type="table-fn"},[\*](#tfn20-ceor-8-377){ref-type="table-fn"}    35                                   Peg-IFN-α + RBV + SOF for 12 weeks                                                                79.63%[b](#tfn9-ceor-8-377){ref-type="table-fn"}                                                 35
  Genotype 2                        SOF + RBV for 12 weeks               97.14%[c](#tfn10-ceor-8-377){ref-type="table-fn"},[\*](#tfn20-ceor-8-377){ref-type="table-fn"}   35                                                                                               Peg-IFN-α + RBV + SOF for 12 weeks   96.00%[d](#tfn11-ceor-8-377){ref-type="table-fn"},[\*](#tfn20-ceor-8-377){ref-type="table-fn"}    36                                                                                               
  Genotype 3                        Peg-IFN-α + RBV + SOF for 12 weeks   90.00%[e](#tfn12-ceor-8-377){ref-type="table-fn"}                                                37                                                                                               Peg-IFN-α + RBV + SOF for 12 weeks   87.93%[f](#tfn13-ceor-8-377){ref-type="table-fn"}                                                 38                                                                                               
  Genotype 4                        OMB/PAR/r + RBV for 12 weeks         100.00%[g](#tfn14-ceor-8-377){ref-type="table-fn"}                                               39                                                                                               OMB/PAR/r + RBV for 12 weeks         100.00%[g](#tfn14-ceor-8-377){ref-type="table-fn"},[\*](#tfn20-ceor-8-377){ref-type="table-fn"}   39                                                                                               
  Genotype 5                        Peg-IFN-α + RBV + SOF for 12 weeks   97.14%[h](#tfn15-ceor-8-377){ref-type="table-fn"},[\*](#tfn20-ceor-8-377){ref-type="table-fn"}   35                                                                                               Peg-IFN-α + RBV + SOF for 12 weeks   79.63%[b](#tfn9-ceor-8-377){ref-type="table-fn"}                                                  35                                                                                               
  Only interferon-free treatments   Genotype 1                           SOF + LDV for 8--12 weeks                                                                        98.60%[i](#tfn16-ceor-8-377){ref-type="table-fn"},[\*](#tfn20-ceor-8-377){ref-type="table-fn"}   40                                   SOF + LDV + RBV for 24 weeks                                                                      99.08%[j](#tfn17-ceor-8-377){ref-type="table-fn"},[\*](#tfn20-ceor-8-377){ref-type="table-fn"}   40
  Genotype 2                        SOF + RBV for 12 weeks               97.14%[c](#tfn10-ceor-8-377){ref-type="table-fn"},[\*](#tfn20-ceor-8-377){ref-type="table-fn"}   35                                                                                               SOF + RBV for 20 weeks               97.14%[c](#tfn10-ceor-8-377){ref-type="table-fn"},[\*](#tfn20-ceor-8-377){ref-type="table-fn"}    35                                                                                               
  Genotype 3                        SOF + RBV for 24 weeks               86.51%[k](#tfn18-ceor-8-377){ref-type="table-fn"}                                                38                                                                                               SOF + DCV + RBV for 24 weeks         57.89%[l](#tfn19-ceor-8-377){ref-type="table-fn"}                                                 41                                                                                               
  Genotype 4                        OMB/PAR/r + RBV for 12 weeks         100.00%[g](#tfn14-ceor-8-377){ref-type="table-fn"}                                               39                                                                                               OMB/PAR/r + RBV for 12 weeks         100.00%[g](#tfn14-ceor-8-377){ref-type="table-fn"},[\*](#tfn20-ceor-8-377){ref-type="table-fn"}   39                                                                                               
  Genotype 5                        SOF + LDV for 12 weeks               98.60%[i](#tfn16-ceor-8-377){ref-type="table-fn"},[\*](#tfn20-ceor-8-377){ref-type="table-fn"}   40                                                                                               SOF + LDV + RBV for 24 weeks         99.08%[j](#tfn17-ceor-8-377){ref-type="table-fn"},[\*](#tfn20-ceor-8-377){ref-type="table-fn"}    40                                                                                               

**Notes:**

Genotype 1 naïve cirrhotic and noncirrhotic patients.

Genotype 1, 4, 5, and 6 naïve cirrhotic patients.

Genotype 2 naïve cirrhotic and noncirrhotic patients.

Genotype 2 naïve and experienced cirrhotic and noncirrhotic patients.

Genotype 3 naïve noncirrhotic patients.

Genotype 3 naïve and experienced cirrhotic patients.

Genotype 4 naïve noncirrhotic patients.

Genotype 4, 5, and 6 naïve cirrhotic and noncirrhotic patients.

Genotype 1 naïve cirrhotic and noncirrhotic patients.

Genotype 1 naïve cirrhotic and noncirrhotic patients.

Genotype 3 naïve and experienced noncirrhotic patients.

Genotype 3 naïve cirrhotic patients.

Due to lack of published data concerning SVR at 12 weeks in the target population, the effectiveness values considered for noncirrhotic patients might be underestimated and the effectiveness values considered for cirrhotic patients might be overestimated.

**Abbreviations:** DCV, Daclatasvir; HCV, hepatitis C virus; LDV, Ledipasvir; OMB, Ombitasvir; PAR, Paritaprevir; Peg-IFN-α: peginterferon-alfa; r, Ritonavir; RBV, Ribavirin; SOF, Sofosbuvir; SVR, sustained virological response.

###### 

Cost of antiviral treatment considered in the analysis

  Antiviral drug                                                   Cost per treatment, € (VAT inclusive)   Source
  ---------------------------------------------------------------- --------------------------------------- ------------
  Daclatasvir                                                      18,700                                  42
  Ombitasvir/Paritaprevir/Ritonavir                                16,353                                  Assumption
  Ombitasvir/Paritaprevir/Ritonavir + Dasabuvir                    19,987                                  Assumption
  Peginterferon-alfa[\^](#tfn22-ceor-8-377){ref-type="table-fn"}   186.1                                   43
  Ribavirine[\^](#tfn22-ceor-8-377){ref-type="table-fn"}           84.1                                    44
  Simeprevir[\*](#tfn23-ceor-8-377){ref-type="table-fn"}           19,800                                  45
  Sofosbuvir                                                       16,353                                  Assumption
  Sofosbuvir + Ledipasvir                                          19,987                                  Assumption

**Notes:**

Cost per week.

Cost of a 12-week treatment.

**Abbreviation:** VAT, value-added tax.

###### 

Estimated direct medical costs (antiviral therapy and monitoring activities) to treat the whole HCV-infected Italian population and year in which HCV prevalence would fall below 100 infected patients (up to 2050)

  Estimated HCV-infected patients   Patients treated per year                         Sole use of interferon-free therapies             Use of interferon and interferon-free therapies                                                     
  --------------------------------- ------------------------------------------------- ------------------------------------------------- ------------------------------------------------- ------------------------------------------------- ------------
  0.3 million                       25,000                                            2030                                              7,177,964                                         2032                                              7,624,657
  50,000                            2023                                              6,980,742                                         2025                                              7,331,094                                         
  75,000                            2021                                              6,918,471                                         2023                                              7,198,620                                         
  100,000                           2020                                              6,896,528                                         2022                                              7,115,776                                         
  0.6 million                       25,000                                            2044                                              14,343,430                                        2046                                              15,418,509
  50,000                            2030                                              13,742,639                                        2032                                              14,563,554                                        
  75,000                            2025                                              13,565,065                                        2027                                              14,280,134                                        
  100,000                           2023                                              13,484,796                                        2025                                              14,123,051                                        
  2.7 million                       25,000                                            2050[a](#tfn25-ceor-8-377){ref-type="table-fn"}   19,434,487                                        2050[b](#tfn26-ceor-8-377){ref-type="table-fn"}   19,373,070
  50,000                            2050[c](#tfn27-ceor-8-377){ref-type="table-fn"}   38,868,973                                        2050[d](#tfn28-ceor-8-377){ref-type="table-fn"}   38,746,140                                        
  75,000                            2050[e](#tfn29-ceor-8-377){ref-type="table-fn"}   57,145,868                                        2050[f](#tfn30-ceor-8-377){ref-type="table-fn"}   57,682,573                                        
  100,000                           2044                                              59,151,269                                        2048                                              63,639,349                                        

**Notes:**

1,280,788 infected patients not treated;

1,292,860 infected patients not treated;

948,526 infected patients not treated;

1,048,528 infected patients not treated;

155,140 infected patients not treated;

339,839 infected patients not treated.

**Abbreviation:** HCV, hepatitis C virus.
